顺式--N,N'-二甲基-1,2-环己二胺 | 75599-23-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 顺式--N,N'-二甲基-1,2-环己二胺
• 英文名称: (1R,2S)-N¹,N²- dimethylcyclohexane-1,2-diamine
• 英文别名: (1R,2R)-N¹,N²-dimethylcyclohexane-1,2-diamine；(1R,2S)-N¹,N²-dimethylcyclohexane-1,2-diamine；(1R,2S)-1-N,2-N- dimethylcyclohexane-1,2-diamine；cis-N,N’-dimethylcyclohexane-1,2-diamine；(1R,2R)-N1,N2-dimethylcyclohexane-1,2-diamine；(1R,2S)-N1,N2-dimethylcyclohexane-1,2-diamine；(1R,2S)-1-N,2-N-dimethylcyclohexane-1,2-diamine
• CAS: 75599-23-4
• 化学式: C₈H₁₈N₂
• 分子量: 142.244
• InChiKey: JRHPOFJADXHYBR-OCAPTIKFSA-N

物化性质

• 沸点：
  186.8±8.0 °C(Predicted)
• 密度：
  0.89±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  顺式--N,N'-二甲基-1,2-环己二胺 以 异戊醇 、 氯仿 为溶剂， 反应 96.0h， 生成 furan-2-carboxylic acid cyclohexyl>methylamide
  参考文献：
  名称：

  Structure-activity relationships in prazosin-related compounds. 2. Role of the piperazine ring on .alpha.-blocking activity

  摘要：

  Several prazosin-related compounds have been synthesized and evaluated for their blocking activity toward a-adrenoreceptors. The structural modification performed on the prazosin structure included the replacement of the piperazine ring with 2,3-dialkylpiperazine or 1,2-cyclohexanediamine moieties to characterize a lipophilic binding pocket in the alpha1-adrenoreceptor surface. Cyclohexanediamine derivatives 3-6 were almost devoid of potency and selectivity, whereas dialkylpiperazine compounds 7-14 showed high affinity and selectivity toward alpha1-adrenoreceptors. The cis derivative 13 (cyclazosin) was the most potent and selective with an alpha1/alpha2 selectivity ratio value of 7800. The particular trend of antagonist activity within cis/trans stereoisomeric compounds not only supports the presence of a lipophilic binding area on alpha1-adrenoreceptor surface but also suggests that the lipophilic pocket is endowed with a well-defined size and spatial orientation. The most active compound of the series, 13, was tested also in vivo for antihypertensive activity on spontaneously hypertensive rats. It showed an interesting long-lasting hypotensive effect, very similar to that of doxazosin, which was statistically significant 12 h after oral administration.

  DOI：

  10.1021/jm00058a005
• 作为产物：
  描述：

  Cis-1,2-diaminocyclohexane 在 lithium aluminium tetrahydride 、 水 作用下， 反应 6.0h， 生成 顺式--N,N'-二甲基-1,2-环己二胺
  参考文献：
  名称：

  芳香醛亚胺衍生物与低价钛试剂还原偶联形成1,2-二芳基乙二胺的应用范围†

  摘要：

  使用低价钛试剂与形成1,2-二芳基乙二胺单元的芳香醛亚胺衍生物进行还原偶联的范围和限制

  DOI：

  10.1002/hlca.19880710818
• 作为试剂：
  描述：

  N-羟甲基邻苯二甲酰亚胺 在 potassium phosphate 、 copper(l) iodide 、 四(三苯基膦)钯 、 硫酸 、 三溴化硼 、 potassium carbonate 、 顺式--N,N'-二甲基-1,2-环己二胺 、 cesium fluoride 、 三氟乙酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 46.0h， 生成
  参考文献：
  名称：

  [EN] PYRIDINYL BASED APOPTOSIS SIGNAL-REGULATION KINASE INHIBITORS
  [FR] INHIBITEURS DE KINASE DE RÉGULATION DU SIGNAL APOPTOTIQUE À BASE DE PYRIDINYLE

  摘要：

  细胞凋亡信号调节激酶1（ASK1）的激活和信号传导据报道在包括神经退行性、心血管、炎症、自身免疫和代谢紊乱等广泛疾病中发挥重要作用。本文披露了一种以吡啶基衍生的治疗剂的合成，其作为ASK1的抑制剂以及它们的药物组合物和使用方法。

  公开号：

  WO2018151830A1

文献信息

• Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
  申请人：——

  公开号：US20030065187A1

  公开（公告）日：2003-04-03

  The present invention relates to copper-catalyzed carbon-heteroatom and carbon-carbon bond-forming methods. In certain embodiments, the present invention relates to copper-catalyzed methods of forming a carbon-nitrogen bond between the nitrogen atom of an amide or amine moiety and the activated carbon of an aryl, heteroaryl, or vinyl halide or sulfonate. In additional embodiments, the present invention relates to copper-catalyzed methods of forming a carbon-nitrogen bond between a nitrogen atom of an acyl hydrazine and the activated carbon of an aryl, heteroaryl, or vinyl halide or sulfonate. In other embodiments, the present invention relates to copper-catalyzed methods of forming a carbon-nitrogen bond between the nitrogen atom of a nitrogen-containing heteroaromatic, e.g., indole, pyrazole, and indazole, and the activated carbon of an aryl, heteroaryl, or vinyl halide or sulfonate. In certain embodiments, the present invention relates to copper-catalyzed methods of forming a carbon-oxygen bond between the oxygen atom of an alcohol and the activated carbon of an aryl, heteroaryl, or vinyl halide or sulfonate. The present invention also relates to copper-catalyzed methods of forming a carbon-carbon bond between a reactant comprising a nucleophilic carbon atom, e.g., an enolate or malonate anion, and the activated carbon of an aryl, heteroaryl, or vinyl halide or sulfonate. Importantly, all the methods of the present invention are relatively inexpensive to practice due to the low cost of the copper comprised by the catalysts.

  本发明涉及铜催化的碳-杂原子和碳-碳键形成方法。在某些实施例中，本发明涉及铜催化的方法，用于在酰胺或胺基团的氮原子与芳基、杂原基或乙烯卤代物或磺酸酯的活化碳之间形成碳-氮键。在其他实施例中，本发明涉及铜催化的方法，用于在酰基肼的氮原子与芳基、杂原基或乙烯卤代物或磺酸酯的活化碳之间形成碳-氮键。在另一些实施例中，本发明涉及铜催化的方法，用于在含氮杂环芳烃（例如吲哚、吡唑和吲哌）的氮原子与芳基、杂原基或乙烯卤代物或磺酸酯的活化碳之间形成碳-氮键。在某些实施例中，本发明涉及铜催化的方法，用于在醇的氧原子与芳基、杂原基或乙烯卤代物或磺酸酯的活化碳之间形成碳-氧键。本发明还涉及铜催化的方法，用于在包含亲核碳原子的反应物（例如烯醇酸盐或丙二酸盐负离子）与芳基、杂原基或乙烯卤代物或磺酸酯的活化碳之间形成碳-碳键。重要的是，由于催化剂中铜的低成本，本发明的所有方法都相对廉价。
• [EN] PYRROLE mTORC INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS PYRROLES DE MTORC ET LEURS UTILISATIONS
  申请人：NAVITOR PHARM INC

  公开号：WO2018089493A1

  公开（公告）日：2018-05-17

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。
• [EN] NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES<br/>[FR] AGONISTES DU RÉCEPTEUR A DU PEPTIDE NATRIURÉTIQUE UTILES POUR LE TRAITEMENT DE MALADIES CARDIOMÉTABOLIQUES, D'UNE MALADIE RÉNALE ET DU DIABÈTE
  申请人：MERCK SHARP & DOHME

  公开号：WO2020236688A1

  公开（公告）日：2020-11-26

  The present invention relates to Compounds of Formula I: I and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment of cardiometabolic diseases including high blood pressure, heart failure, kidney disease, and diabetes in a subject.

  本发明涉及公式I的化合物：I及其药用可接受的盐或前药。本发明还涉及包含至少一种公式I化合物的组合物，以及使用公式I化合物治疗心脏代谢疾病，包括高血压、心力衰竭、肾脏疾病和糖尿病的方法。
• [EN] SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS<br/>[FR] DÉRIVÉS SUBSTITUÉS DE L'ACIDE ARYLSULFONYLAMINOMÉTHYLPHOSPHONIQUE, LEUR PRÉPARATION ET LEUR UTILISATION POUR TRAITER LE DIABÈTE SUCRÉ DE TYPE I ET DE TYPE II
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009016118A1

  公开（公告）日：2009-02-05

  The present invention relates to substituted arylsulphonylaminomethylphosphonic acid derivatives of general formula (I) wherein R, X, Y and Z are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and salts thereof which have valuable pharmacological properties, particularly the suppression of the interaction of glycogen phosphorylase a with the GL subunit of glycogen-associated protein phosphatase 1 (PP1), and their use as pharmaceutical compositions.

  本发明涉及取代的芳基磺酰氨基甲基磷onic acid衍生物，其具有通式（I），其中R，X，Y和Z如权利要求1中定义，其互变异构体，对映体，非对映体，混合物及其盐具有宝贵的药理性质，尤其是抑制糖原磷酸化酶a与糖原相关蛋白磷酸酶1（PP1）的GL亚基之间的相互作用，以及它们作为药物组合物。
• DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS
  申请人：Connolly Peter J.

  公开号：US20120058986A1

  公开（公告）日：2012-03-08

  Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein Q and Z are defined herein.

  揭示了用于治疗各种疾病、综合症、症状和障碍的化合物、组合物和方法，包括疼痛。这些化合物由以下式（I）表示： 其中Q和Z在此处定义。